Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Rhea-AI Summary

Endo International plc (OTC: ENDPQ) has initiated shipments of argatroban injection to healthcare providers via Premier's Premier ProRx^® program as of April 17, 2023. This product addresses ongoing supply challenges in the market and is listed as an essential medication by the FDA. The manufacturing occurs at Endo's facility in Rochester, Michigan. This introduction marks the third product supplied to Premier's hospital clients, alongside Adrenalin, Vasostrict, and fluphenazine decanoate injection. The partnership aims to enhance drug supply reliability in the healthcare sector.

Positive

• Shipping argatroban injection through Premier ProRx program enhances supply reliability.
• Argatroban is part of the FDA's essential medications list.
• Expansion of product offerings through reliable Premier ProRx channel.

Negative

• Supply issues of argatroban in the broader market persist.
• Company faces potential risks related to ongoing litigation and restructuring activities.

DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping argatroban injection to healthcare providers through Premier's Premier ProRx^® private-label program, a guaranteed supply for hospitals and health systems.

Argatroban is on FDA's essential medications list and has experienced intermittent supply issues in the broader market.

"We're pleased to join Premier in helping to address industry drug supply and serving as a guaranteed supplier of argatroban, manufactured in our Rochester, Michigan facility," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We're proud to now provide a third product through the reliable Premier ProRx^® supply channel."

Endo also supplies its Adrenalin^® (epinephrine injection, USP), Vasostrict^® (vasopressin injection, USP) and fluphenazine decanoate injection, USP products to Premier's hospital customers through the Premier ProRx^® private-label program.

About Endo
Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

About Par Pharmaceutical
Par Pharmaceutical develops, manufactures and markets innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patients' lives. Par, among the top leaders in the U.S. generics industry, possesses an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. Par Pharmaceutical is an Endo company. Learn more at www.parpharm.com.

Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. Sims and any statements relating to product launch, shipment, sales, supply or distribution, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; any actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the risks and uncertainties associated with chapter 11 proceedings; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the risk that the Company's chapter 11 cases may be converted to cases under chapter 7 of the Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results; the Company's ability to discharge claims in chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; the risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in chapter 11 proceedings; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; and the Company's ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.

Additional information concerning risk factors, including those referenced above, can be found in press releases issued by the Company, as well as the Company's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.

View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-announces-launch-of-argatroban-injection-through-premiers-prorx-private-label-program-301798325.html

SOURCE Endo International plc

FAQ

What is the significance of Endo's argatroban injection announcement on April 17, 2023?

Endo's announcement signifies the start of shipments of argatroban injection through Premier ProRx, addressing market supply issues.

How does argatroban injection relate to the FDA's essential medications list?

Argatroban injection is included on the FDA's essential medications list, highlighting its importance in healthcare.

What other products does Endo supply through Premier ProRx?

Endo also supplies Adrenalin, Vasostrict, and fluphenazine decanoate injection through Premier ProRx.